

Review Article

# Prenatal diagnosis and genetic analysis of fetal akinesia deformation sequence and multiple pterygium syndrome associated with neuromuscular junction disorders: A review

Chih-Ping Chen <sup>a,b,c,d,e,f,g,\*</sup>

<sup>a</sup> Department of Medicine, Mackay Medical College, New Taipei City, Taiwan

<sup>b</sup> Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan

<sup>c</sup> Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan

<sup>d</sup> Department of Biotechnology, Asia University, Taichung, Taiwan

<sup>e</sup> School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan

<sup>f</sup> Institute of Clinical and Community Health Nursing, National Yang-Ming University, Taipei, Taiwan

<sup>g</sup> Department of Obstetrics and Gynecology, School of Medicine, National Yang-Ming University, Taipei, Taiwan

Accepted 6 January 2012

## Abstract

Fetal akinesia deformation sequence is a clinically and genetically heterogeneous disorder characterized by a variable combination of arthrogryposis, fetal akinesia, intrauterine growth restriction, developmental abnormalities such as cystic hygroma, pulmonary hypoplasia, cleft palate, cryptorchidism, cardiac defects and intestinal malrotation, and occasional pterygia of the limbs. Multiple pterygium syndrome is a clinically and genetically heterogeneous disorder characterized by pterygia of the neck, elbows and/or knees, arthrogryposis, and other phenotypic features such as short stature, genital abnormalities, craniofacial abnormalities, clubfoot, kyphoscoliosis, and cardiac abnormalities. Fetal akinesia deformation sequence may phenotypically overlap with the lethal type of multiple pterygium syndrome. This article provides a comprehensive review of prenatal diagnosis and genetic analysis of fetal akinesia deformation sequence and multiple pterygium syndrome associated with neuromuscular junction disorders. Prenatal diagnosis of fetal akinesia along with cystic hygroma, increased nuchal translucency, nuchal edema, hydrops fetalis, arthrogryposis, pterygia, and other structural abnormalities should include a differential diagnosis of neuromuscular junction disorders. Genetic analysis of mutations in the neuromuscular junction genes such as *CHRNA1*, *CHRND*, *CHRNA3*, *CNTN1*, *DOK7*, *RAPSN*, and *SYNE1* may unveil the pathogenetic cause of fetal akinesia deformation sequence and multiple pterygium syndrome, and the information acquired is helpful for genetic counseling and clinical management.

Copyright © 2012, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.

**Keywords:** *CHRNA1*; *CHRND*; *CHRNA3*; *CNTN1*; *DOK7*; fetal akinesia deformation sequence; multiple pterygium syndrome; prenatal diagnosis; *RAPSN*; *SYNE1*

## Introduction

Fetal akinesia deformation sequence (FADS; OMIM 208150) is a clinically and genetically heterogeneous disorder characterized by a variable combination of arthrogryposis,

fetal akinesia, intrauterine growth restriction (IUGR), developmental abnormalities such as cystic hygroma, pulmonary hypoplasia, cleft palate, cryptorchidism, cardiac defects and intestinal malrotation, and occasional pterygia of the limbs [1–5]. In a retrospective population-based study in Denmark, Bayat et al [6] reported that the incidence of FADS was 1:15,000. FADS was originally reported by Pena and Shokeir [1] and Lindhout et al [3] to describe a disorder called Pena–Shokeir syndrome consisting of the symptoms of IUGR, polyhydramnios, facial dysmorphism, pulmonary hypoplasia,

\* Department of Obstetrics and Gynecology, Mackay Memorial Hospital, 92, Section 2, Chung-Shan North Road, Taipei, Taiwan.

E-mail address: [cpc\\_mmh@yahoo.com](mailto:cpc_mmh@yahoo.com)

a short umbilical cord, and supplementary symptoms of cleft or high-arched palate and bell-shaped chest. The pathogenetic mechanisms of FADS include neuropathy, muscular disorders, neuromuscular junction (NMJ) disorders, maternal myasthenia gravis, restrictive dermopathy, and others [5,7–12]. FADS may phenotypically overlap with the lethal type of multiple pterygium syndrome (LMPS; OMIM 253290). Multiple pterygium syndrome (MPS) is a clinically and genetically heterogeneous disorder characterized by pterygia (webbing) of the neck, elbows and/or knees, arthrogyrosis (joint contractures), and other phenotypic features such as short stature, genital abnormalities, craniofacial abnormalities, clubfoot, kyphoscoliosis, and cardiac abnormalities [13–15]. MPS can occur in autosomal-recessive [12,16–18], autosomal-dominant [19], or X-linked-dominant [20] transmission.

### Genetic analysis of mutations in the genes associated with NMJ in fetuses with FADS/MPS

FADS and/or MPS have been reported to be caused by mutations in the genes associated with NMJ such as *CHRNA1* (OMIM 100690), *CHRND* (OMIM 100720), *CHRNA1* (OMIM 100730), *RAPSN* (OMIM 601592), *DOK7* (OMIM 610285), *CNTN1* (OMIM 600016), and *SYNE1* (OMIM 608441).

#### *CHRNA1*

*CHRNA1*, *CHRN1* (OMIM 100710), *CHRND*, *CHRNA1*, and *CHRNA1* (OMIM 100725) encode the acetylcholine receptor (AChR) subunits of  $\alpha 1$ ,  $\beta 1$ ,  $\delta$ ,  $\gamma$ , and  $\epsilon$ , respectively. The AChR of fetal type consists of  $\alpha 1$  (two) subunits and one of each  $\beta 1$ ,  $\delta$ , and  $\gamma$  subunits, whereas the AChR of adult type consists of two  $\alpha 1$ ,  $\beta 1$ ,  $\delta$ , and  $\epsilon$  subunits because of replacement of the fetal  $\gamma$  subunit by the adult  $\epsilon$  subunit after 33 weeks of gestation [21–23]. Heterozygous mutations of *CHRNA1* can cause autosomal dominant congenital slow-channel myasthenic syndrome (OMIM 601462) and congenital fast-channel myasthenic syndrome (OMIM 608930). Homozygous mutations of *CHRNA1* have been reported to cause autosomal-recessive LMPS [12]. Michalk et al [12] reported two male sib fetuses in a consanguineous Pakistani family with LMPS and a homozygous mutation of c.761 G→T in *CHRNA1* that predicts R234L in mature protein and R245L in precursor. The first fetus was stillborn at 24 weeks of gestation with IUGR, edema, cystic hygroma, decreased movements, joint contractures, faciocranial dysmorphism, cleft palate, micrognathia, reduced muscle bulk, scoliosis, contractures, and pterygia. The second fetus was terminated at 20 weeks of gestation with similar phenotypic features as the first fetus and an additional finding of rocker-bottom feet. Michalk et al [12] reported another two male sib fetuses in a non-consanguineous African family with LMPS and a homozygous mutation of c.117\_133dup17 in *CHRNA1* that predicts H25RfsX19 in mature protein or H45RfsX19 in precursor. The first fetus was stillborn at 28 weeks of gestation. The second fetus was terminated at 17 weeks of gestation with IUGR, edema, cystic hygroma at 7 weeks of gestation, decreased movements, joint contractures,

faciocranial dysmorphism, down-slanting palpebral fissures, a depressed nasal bridge, micrognathia, low-set ears, contractures, and pterygia.

#### *CHRND*

Heterozygous mutations of *CHRND* can cause autosomal-dominant congenital slow-channel myasthenic syndrome and congenital fast-channel myasthenic syndrome. Homozygous or compound heterozygous mutations in *CHRND* have been reported to cause autosomal recessive LMPS [12]. Michalk et al [12] reported two male sib fetuses in a consanguineous Turkish family with LMPS and a homozygous mutation of c.234 G→A in *CHRND* that predicts W57X in mature protein or W78X in precursor. Both fetuses were terminated at 15 weeks of gestation and manifested IUGR, edema, cystic hygroma, decreased movements, and joint contractures. One fetus additionally showed cystic hygroma, muscle hypoplasia, scoliosis, contractures, pectus excavatum, broad ribs and clavicles, and pterygia. Michalk et al [12] also reported five sib fetuses in a non-consanguineous German family with LMPS and compound heterozygous mutations of c.283 T→C/c.1390C→T in *CHRND* that predict F74L/R443X in mature protein or F95L/R464X in precursor. The first female fetus was delivered at 23 gestational weeks with neonatal death, generalized edema, a depressed nasal bridge, low-set ears, a big atrial septal defect, lung hypoplasia, hydrothorax, and ascites. The second female fetus was terminated at 19 gestational weeks with cystic hygroma, joint contractures, faciocranial dysmorphism, hypertelorism, a depressed nasal bridge, micrognathia, low-set ears, contractures, pterygia, rocker-bottom feet, lung hypoplasia, hydrothorax, pericardial effusion, and shortened ribs. The third male fetus was terminated at 12 gestational weeks with cystic hygroma, decreased movements, joint contractures, contractures, and pterygia. The fourth male fetus was terminated at 13 gestational weeks with IUGR, cystic hygroma, decreased movements, joint contractures, micrognathia, low-set ears, contractures, and pterygia. The fifth male fetus was terminated at 19 gestational weeks with IUGR, edema, cystic hygroma, joint contractures, faciocranial dysmorphism, down-slanting palpebral fissures, hypertelorism, a depressed nasal bridge, micrognathia, low-set ears, contractures, and pterygia.

#### *CHRNA1*

Homozygous and compound heterozygous mutations in *CHRNA1* have been reported to cause autosomal-recessive Escobar syndrome (OMIM 265000) and LMPS [18,24]. Morgan et al [18] reported two sibs of different sex in a consanguineous Arab family with LMPS and a homozygous missense mutation of c.320 T→G in *CHRNA1* that predicts p.Val107Gly. The sister died at age 3 months because of congenital heart disease, and the brother died at age 3 days because of lung hypoplasia. Morgan et al [18] also reported a male fetus in a consanguineous Turkish family with LMPS and a homozygous frameshift mutation of c.753\_754delCT in

*CHRNA1* that predicts p.Val253AlafsX44. The fetus manifested hydrops at 13 weeks of gestation and was terminated at 15 weeks of gestation with down-slanting palpebral fissures, low-set ears, micrognathia, deviation of the wrists, bilateral talipes, unfixed colon, mild thoracic scoliosis, and reduced muscle bulk. Morgan et al [18] additionally reported a 37-gestational-week female fetus in a non-consanguineous family with hydrops, bilateral pleural effusions, skin edema, hydronephrotic right kidney, pterygia, rocker-bottom feet, lung hypoplasia, neonatal death, and a homozygous frameshift mutation of c.459dupA in *CHRNA1* that predicts p.Val1154SerfsX24.

### RAPSN

The *RAPSN* gene encodes a postsynaptic protein that functions as a link between AchR and the agrin-binding dystrophin-associated glycoprotein complex to stabilize AchR at the NMJ [25]. Homozygous or compound heterozygous mutations in *RAPSN* can cause autosomal recessive FADS and congenital myasthenic syndrome associated with AchR deficiency (OMIM 608931). Michalk et al [12] reported two sibs of different sex with FADS in a non-consanguineous Pakistani family. The sibs were born at term with severe respiratory problems, inborn contractures, down-slanting palpebral fissures, mild hypertelorism, a wide nasal bridge, low-set ears, micrognathia, a small mouth, tented lips, hypotonia, but no pterygia. The brother had cryptorchidism and died of respiratory problems at age 10 months, and the sister had cleft palate but was alive at age 10 months. Both sibs had compound heterozygous mutations of c.416 T → C / c.566 C → T in *RAPSN* that predict F139S/A189 V. Vogt et al [5] reported three sibs (two twin males and one female) with FADS and a homozygous mutation of c.1177\_1178delAA in *RAPSN* that predicts a frameshift after residue 392 of rapsyn resulting in 82 C-terminal missense amino acids. The monozygotic twin males were found to have FADS, micrognathia, fixed position of the extremities, a small thorax, no respiratory movements, and mild hydrops at 19 weeks of gestation. The pregnancy was terminated at 23 weeks of gestation, and the fetuses manifested a flat facial profile, hypertelorism, moderate micrognathia, a short broad neck, mild hydrops, hydrothorax, subcutaneous edema, hypoplastic lungs, abnormal posture, hyperextension of the wrists, flexion of the fingers, fixed ankles, hyperextended toes, but no pterygia. The female singleton was found to have FADS at 19 weeks of gestation, and the pregnancy was terminated at 23 weeks of gestation. The fetus postnatally manifested micrognathia, low-set ears, a short nose, a short philtrum, thin lips, a short broad neck, subcutaneous edema of the head, neck and shoulders, abnormally fixed elbows, hyperextended wrists, and overlapping fingers, but no pterygia.

### DOC7

The *DOC7* gene encodes a muscle protein that is essential for synaptogenesis through its interaction with MuSK (OMIM 601296), a skeletal muscle receptor tyrosine kinase that

orchestrates postsynaptic differentiation including the clustering of receptors for the neurotransmitter acetylcholine [26]. Homozygous or compound heterozygous mutations in *DOC7* can cause autosomal recessive FADS and familial limb-girdle myasthenia (OMIM 254300). Vogt et al [5] identified a homozygous *DOC7* splice site mutation of IVS3+1 G > T or c.331 + 1 G > T in a consanguineous Bengali family with three fetuses affected with FADS but no pterygia. The first fetus was stillborn at 32 weeks of gestation with a neuromuscular disorder. The second fetus was miscarried at 22 weeks of gestation with down-slanting palpebral fissures, a small jaw, a short neck, extended extremities, overlapping fingers, bilateral talipes, rocker-bottom feet, bilateral hydrothorax, severe generalized edema, and reduced muscle bulk. The third fetus was found to have no fetal movements on prenatal ultrasound at 24 weeks of gestation.

### CNTN1

The *CNTN1* gene encodes a neural adhesion and NMJ protein that is restricted to the NMJ and function for NMJ adhesion [27]. Homozygous mutations in *CNTN1* can cause severe fetal akinesia and Compton–North congenital myopathy (OMIM 612540). Compton et al [27] identified a homozygous 1-bp duplication (c.871dupT) in exon 8 of *CNTN1* that results in a frameshift and premature truncation (S291fsX296) within the third Ig domain and predicts a nonsense-mediated mRNA decay.

### SYNE1

The *SYNE1* gene encodes a synaptic nuclear envelope protein 1 or nesprin 1. Nesprin 1 anchors specialized myonuclei underneath NMJ, binds lamin A and emerin, and interacts with the cytoplasmic domain of MuSK [28–31]. Mutations in *SYNE1* can cause autosomal-recessive spinocerebellar ataxia 8 (OMIM 610743), autosomal-dominant Emery–Dreifuss muscular dystrophy 4 (OMIM 612998), and autosomal-recessive myogenic arthrogryposis multiplex congenita [32]. Attali et al [32] identified homozygosity for an acceptor site mutation 2-bp 5' to exon 137 in *SYNE1* (IVS136-2 A > G) that predicts retention of intron 136 in mRNA and generates a premature stop codon and loss of the C-terminal transmembrane KASH domain in a two-generation consanguineous family with arthrogryposis, decreased fetal movements, hypotonia, delayed motor milestones, and progressive motor decline after the first decade. In that family, a brother of affected children married his first cousin who had two pregnancies that manifested bilateral clubfeet and decreased fetal movements at 28 and 16 weeks of gestation in the first and second fetuses, respectively.

### Prenatal diagnosis of FADS/MPS by ultrasound and magnetic resonance imaging

Prenatal diagnosis of reduced or absent fetal movements in association with abnormal fetal posture should include

a differential diagnosis of spina bifida, trisomy 18, arthrogryposis, FADS, fetal constraint, body stalk anomaly, caudal regression sequence, fetal hypoxia/severe hypotonia, amniotic bands, fetal neck masses, joint dislocations, vertebral segmentation abnormalities, iniencephaly, and MPS [33]. Fetal akinesia/arthrogryposis can result from primary defects of brain, spinal cord, peripheral nerves, NMJ, skeletal musculature and connective tissues, vascular compromise, restricted intrauterine space, teratogenic exposures, ischemia, maternal illness, and circulating maternal antibodies to neurotransmitters, myelin, and muscle proteins [34,35]. Fetal akinesia can be detected by prenatal ultrasound as early as 12 weeks of gestation [36]. Prenatal ultrasound findings of fetal akinesia/arthrogryposis include lack of extremity motions, persistent abnormal posture of the limbs, lack of facial movements, polyhydramnios due to decreased fetal swallowing, pulmonary hypoplasia, a short umbilical cord due to decreased fetal movements, IUGR, increased nuchal translucency, nuchal edema or cystic hygroma in the first trimester, and hydrops fetalis [36–65]. Fetal magnetic resonance imaging can be a useful adjunct to prenatal ultrasound in evaluating central nervous system findings [62,65]. The abnormal neurological magnetic resonance imaging findings include agenesis of the corpus callosum, lissencephaly, hydrocephalus, and spinal cord abnormalities [37]. Prenatal ultrasound findings of Escobar MPS include small stature, multiple pterygia of neck, axillae, elbows and knees, micrognathia, digital hypoplasia, camptodactyly, syndactyly, and scoliosis [66]. Prenatal ultrasound findings with LMPS include IUGR, flexion contractures of the limbs, multiple extensive pterygia, cystic hygroma, hydrops, and hypoplastic lungs [67–77].

In summary, this article provides a comprehensive review of prenatal diagnosis and genetic analysis of FADS/MPS associated with NMJ disorders. Prenatal diagnosis of fetal akinesia along with cystic hygroma, increased nuchal translucency, nuchal edema, hydrops fetalis, arthrogryposis, pterygia, and other structural abnormalities should include a differential diagnosis of NMJ disorders. Genetic analysis of mutations in the genes associated with NMJ may unveil the pathogenetic cause of FADS/MPS, and the information acquired is helpful for genetic counseling and clinical management.

## Acknowledgments

This work was supported by research grants NSC-97-2314-B-195-006-MY3 and NSC-99-2628-B-195-001-MY3 from the National Science Council, and MMH-E-100-04 from Mackay Memorial Hospital, Taipei, Taiwan.

## References

- [1] Pena SD, Shokeir MH. Syndrome of camptodactyly, multiple ankyloses, facial anomalies and pulmonary hypoplasia: a lethal condition. *J Pediatr* 1974;85:373–5.
- [2] Hall JG, Reed SD, Rosenbaum KN, Gershanik J, Chen H, Wilson KM. Limb pterygium syndromes: a review and report of eleven patients. *Am J Med Genet* 1982;12:377–409.
- [3] Lindhout D, Hageman G, Beemer FA, Ippel PF, Breslau-Siderius L, Willemse J. The Pena–Shokeir syndrome: report of nine Dutch cases. *Am J Med Genet* 1985;21:655–68.
- [4] Moessinger AC. Fetal akinesia deformation sequence: an animal model. *Pediatrics* 1983;72:857–63.
- [5] Vogt J, Morgan NV, Marton T, Maxwell S, Harrison BJ, Beeson D, et al. Germline mutation in *DOK7* associated with fetal akinesia deformation sequence. *J Med Genet* 2009;46:338–40.
- [6] Bayat A, Petersen A, Möller M, Andersen G, Ebbesen F. Incidence of fetal akinesia–hypokinesia deformation sequence: a population-based study. *Acta Paediatr* 2009;98:3–4.
- [7] Hall JG. Analysis of Pena–Shokeir phenotype. *Am J Med Genet* 1986;25:99–117.
- [8] Rodríguez JI, Palacios J. Pathogenetic mechanisms of fetal akinesia deformation sequence and oligohydramnios sequence. *Am J Med Genet* 1991;40:284–9.
- [9] Brueton LA, Husom SM, Cox PM, Shirley I, Thompson EM, Barnes PRJ, et al. Asymptomatic maternal myasthenia as cause of the Pena–Shokeir phenotype. *Am J Med Genet* 2000;92:1–6.
- [10] Nijsten TEC, De Moor A, Colpaert CG, Robert K, Mahieu LM, Lambert J. Restrictive dermatopathy: a case report and a critical review of all hypotheses of its origin. *Pediatr Dermatol* 2002;19:67–72.
- [11] Witters I, Moerman P, Fryns J-P. Fetal akinesia deformation sequence: a study of 30 consecutive *in utero* diagnoses. *Am J Med Genet* 2002;113:23–8.
- [12] Michalk A, Stricker S, Becker J, Rupps R, Pantzar T, Miertus J, et al. Acetylcholine receptor pathway mutations explain various fetal akinesia deformation sequence disorders. *Am J Hum Genet* 2008;82:464–76.
- [13] Escobar V, Bixler D, Gleiser S, Weaver DD, Gibbs T. Multiple pterygium syndrome. *Am J Dis Child* 1978;132:609–11.
- [14] Ramer JC, Ladda RL, Demuth WW. Multiple pterygium syndrome. An overview. *Am J Dis Child* 1988;142:794–8.
- [15] Teebi AS, Daoud AS. Multiple pterygium syndrome: a relatively common disorder among Arabs. *J Med Genet* 1990;27:791.
- [16] Chen H, Chang CH, Misra RP, Peters HA, Grijalva NS, Opitz JM. Multiple pterygium syndrome. *Am J Med Genet* 1980;7:91–102.
- [17] Fenoll B, Rigault P, Maroteaux P, Padovani JP, Guyonvarch G, Durand Y. Multiple pterygium syndrome in children. 7 cases. *Rev Chir Orthop Reparatrice Appar Mot* 1990;76:102–11 [French].
- [18] Morgan NV, Brueton LA, Cox P, Grealley MT, Tolmie J, Pasha S, et al. Mutations in the embryonal subunit of the acetylcholine receptor (*CHRNA3*) cause lethal and Escobar variants of multiple pterygium syndrome. *Am J Hum Genet* 2006;79:390–5.
- [19] McKeown CME, Harris R. An autosomal dominant multiple pterygium syndrome. *J Med Genet* 1988;25:96–103.
- [20] Carnevale A, López Hernández A, De los Cobos L. Familial pterygium syndrome with probably dominant transmission linked to the X chromosome. *Rev Invest Clin* 1973;25:237–44 [Spanish].
- [21] Hesselmann LFGM, Jennekens FGI, Van den Oord CJM, Veldman H, Vincent A. Development of innervation of skeletal muscle fibers in man: relation to acetylcholine receptors. *Anat Rec* 1993;236:553–62.
- [22] Missias AC, Chu GC, Klocke BJ, Sanes JR, Merlie JP. Maturation of the acetylcholine receptor in skeletal muscle: regulation of the AChR  $\gamma$ -to- $\epsilon$  switch. *Dev Biol* 1996;179:223–38.
- [23] Yumoto N, Wakatsuki S, Sehara-Fujisawa A. The acetylcholine receptor  $\gamma$ -to- $\epsilon$  switch occurs in individual endplates. *Biochem Biophys Res Commun* 2005;331:1522–7.
- [24] Hoffmann K, Müller JS, Stricker S, Megarbane A, Rajab A, Lindner TH, et al. Escobar syndrome is a prenatal myasthenia caused by disruption of the acetylcholine receptor fetal  $\gamma$  subunit. *Am J Hum Genet* 2006;79:303–12.
- [25] Apel ED, Roberds SL, Campbell KP, Merlie JP. Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoprotein complex. *Neuron* 1995;15:115–26.
- [26] Okada K, Inoue A, Okada M, Murata Y, Kakuta S, Jigami T, et al. The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. *Science* 2006;312:1802–5.



- [27] Compton AG, Albrecht DE, Seto JT, Cooper ST, Ilkovski B, Jones KJ, et al. Mutations in contactin-1, a neural adhesion and neuromuscular junction protein, cause a familial form of lethal congenital myopathy. *Am J Hum Genet* 2008;83:714–24.
- [28] Apel ED, Lewis RM, Grady RM, Sanes JR. Syne-1, a dystrophin- and Klarsicht-related protein associated with synaptic nuclei at the neuromuscular junction. *J Biol Chem* 2000;275:31986–95.
- [29] Zhang Q, Skepper JN, Yang F, Davies JD, Hegyi L, Roberts RG, et al. Nesprins: a novel family of spectrin-repeat-containing proteins that localize to the nuclear membrane in multiple tissues. *J Cell Sci* 2001;114:4485–98.
- [30] Mislow JMK, Holaska JM, Kim MS, Lee KK, Segura-Totten M, Wilson KL, et al. Nesprin-1 $\alpha$  self-associates and binds directly to emerin and lamin A *in vitro*. *FEBS Lett* 2002;525:135–40.
- [31] Crisp M, Liu Q, Roux K, Rattner JB, Shanahan C, Burke B, et al. Coupling of the nucleus and cytoplasm: role of the LINC complex. *J Cell Biol* 2006;172:41–53.
- [32] Attali R, Warwar N, Israel A, Gurt I, McNally E, Puckelwartz M, et al. Mutation of *SYNE-1*, encoding an essential component of the nuclear lamina, is responsible for autosomal recessive arthrogryposis. *Hum Mol Genet* 2009;18:3462–9.
- [33] Byrne JLB. 7 musculoskeletal: abnormal fetal posture/movement. In: Woodward PJ, Kennedy A, Sohaey R, Byrne JLB, Oh KY, Puchalski MD, editors. *Expertddx: obstetrics*. 1st ed. Salt Lake City, UT: Amirsys Inc; 2009. p. 2–7.
- [34] Ravenscroft G, Sillis E, Charles AK, North KN, Baynam G, Laing NG. Fetal akinesia: review of the genetics of the neuromuscular causes. *J Med Genet* 2011;48:793–801.
- [35] Rink BD. Arthrogryposis: a review and approach to prenatal diagnosis. *Obstet Gynecol Surv* 2011;66:369–77.
- [36] Hall JG. Pena–Shokeir phenotype (fetal akinesia deformation sequence) revisited. *Birth Defects Res A Clin Mol Teratol* 2009;85:677–94.
- [37] Byrne JLB. 10 musculoskeletal: arthrogryposis, akinesia sequence. In: Woodward PJ, Kennedy A, Sohaey R, Byrne JLB, Oh KY, Puchalski MD, editors. *Diagnostic imaging: obstetrics*. 1st ed. Salt Lake City, UT: Amirsys Inc; 2005. p. 54–7.
- [38] MacMillan RH, Harbert GM, Davis WD, Kelly TE. Prenatal diagnosis of Pena–Shokeir syndrome type I. *Am J Med Genet* 1985;21:279–84.
- [39] Shenker L, Reed K, Anderson C, Hauck L, Spark R. Syndrome of camptodactyly, ankyloses, facial anomalies, and pulmonary hypoplasia (Pena–Shokeir syndrome): obstetric and ultrasound aspects. *Am J Obstet Gynecol* 1985;152:303–7.
- [40] Muller LM, de Jong G. Prenatal ultrasonographic features of the Pena–Shokeir I syndrome and the trisomy 18 syndrome. *Am J Med Genet* 1986;25:119–29.
- [41] Cardwell MS. Pena–Shokeir syndrome. Prenatal diagnosis by ultrasonography. *J Ultrasound Med* 1987;6:619–21.
- [42] Kirkinen P, Herva R, Leisti J. Early prenatal diagnosis of a lethal syndrome of multiple congenital contractures. *Prenat Diagn* 1987;7:189–96.
- [43] Ohlsson A, Fong KW, Rose TH, Moore DC. Prenatal sonographic diagnosis of Pena–Shokeir syndrome type I, or fetal akinesia deformation sequence. *Am J Med Genet* 1988;29:59–65.
- [44] Persutte WH, Lenke RR, Kurczynski TW, Brinker RA. Antenatal diagnosis of Pena–Shokeir syndrome (type I) with ultrasonography and magnetic resonance imaging. *Obstet Gynecol* 1988;72:472–5.
- [45] Genkins SM, Hertzberg BS, Bowie JD, Blow O. Pena–Shokeir type I syndrome: *in utero* sonographic appearance. *J Clin Ultrasound* 1989;17:56–61.
- [46] Oberlechner E, Seidel H, Stechele F, Högel B, Fichtel G, Schramm T, et al. Prenatal diagnosis of familial akinesia-hypokinesia sequence (Pena–Shokeir phenotype). *Gynakol Rundsch* 1989;29:292–3 [German].
- [47] Oberlechner E, Seidel H, Schramm T, Rehder H, Gullotta F, Stechele F, et al. Familial akinesia–hypokinesia sequence (Pena–Shokier phenotype). *Geburtshilfe Frauenheilkd* 1994;54:276–85 [German].
- [48] Wieacker P, Wilhelm C, Böhm N, Schillinger H. Prenatal diagnosis of Pena–Shokeir syndrome in the 27th week of pregnancy. *Geburtshilfe Frauenheilkd* 1990;50:155–7 [German].
- [49] Gyr T, Katz M, Altermatt HJ, Braga S, Duerig P, Koenig C, et al. Lethal Pena–Shokeir 1 syndrome in three male siblings. *Arch Gynecol Obstet* 1992;251:149–54.
- [50] Ajayi RA, Keen CE, Knott PD. Ultrasound diagnosis of the Pena Shokeir phenotype at 14 weeks of pregnancy. *Prenat Diagn* 1995;15:762–4.
- [51] Horrow MM, Rosenberg HK, Schneider AS, Greenberg CM, Zaeri N. US case of the day. Pena–Shokeir phenotype. *Radiographics* 1995;15:726–9.
- [52] Hyett J, Noble P, Sebire NJ, Snijders R, Nicolaides KH. Lethal congenital arthrogryposis presents with increased nuchal translucency at 10–14 weeks of gestation. *Ultrasound Obstet Gynecol* 1997;9:310–3.
- [53] Souka AP, Snijders RJM, Novakov A, Soares W, Nicolaides KH. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10–14 weeks of gestation. *Ultrasound Obstet Gynecol* 1998;11:391–400.
- [54] Scott H, Hunter A, Bédard B. Non-lethal arthrogryposis multiplex congenita presenting with cystic hygroma at 13 weeks gestational age. *Prenat Diagn* 1999;19:966–71.
- [55] Tongsong T, Chanprapaph P, Khunamornpong S. Prenatal ultrasound of regional akinesia with Pena–Shokier phenotype. *Prenat Diagn* 2000;20:422–5.
- [56] Ochi H, Kobayashi E, Matsubara K, Katayama T, Ito M. Prenatal sonographic diagnosis of Pena–Shokeir syndrome type I. *Ultrasound Obstet Gynecol* 2001;17:546–7.
- [57] Paladini D, Tartaglione A, Agangi A, Foglia S, Martinelli P, Nappi C. Pena–Shokeir phenotype with variable onset in three consecutive pregnancies. *Ultrasound Obstet Gynecol* 2001;17:163–5.
- [58] Makrydimas G, Sotiriadis A, Papapanagiotou G, Tsopelas A, Lolis D. Fetal akinesia deformation sequence presenting with increased nuchal translucency in the first trimester of pregnancy. *Fetal Diagn Ther* 2004;19:332–5.
- [59] Giordano G, Gnetti L, Froio E, Ricci R. Early fetal akinesia deformation sequence: a case report with unusual autoptic features. *J Matern Fetal Neonatal Med* 2005;17:349–52.
- [60] Dzinović A, Heljić S. Pena–Shokeir phenotype (fetal akinesia/hypokinesia sequence). *Med Arh* 2006;60:383–5 [Bosnian].
- [61] Eguluz I, Barber MA, Martín A, Plasencia W, Arencibia O. Fetal akinesia deformation sequence. Pena–Shokeir type I syndrome: new features of an un-uncommon condition. *J Obstet Gynaecol* 2006;26:818–20.
- [62] Senocak EU, Oguz KK, Haliloglu G, Karcaaltincaba D, Akata D, Kandemir O. Prenatal diagnosis of Pena–Shokeir syndrome phenotype by ultrasonography and MR imaging. *Pediatr Radiol* 2009;39:377–80.
- [63] Deli T, Kovács T. Pena–Shokeir syndrome type I — combination of polyhydramnios and pulmonary hypoplasia in fetal akinesia. *Orv Hetil* 2010;151:990–3 [Hungarian].
- [64] Gupta P, Sharma JB, Sharma R, Gadodia A, Kumar S, Roy KK. Antenatal ultrasound and MRI findings of Pena–Shokeir syndrome. *Arch Gynecol Obstet* 2011;283:27–9.
- [65] Nemeč SF, Hoftberger R, Nemeč U, Bettelheim D, Brugger PC, Kasprian G, et al. Fetal akinesia and associated abnormalities on prenatal MRI. *Prenat Diagn* 2011;31:484–90.
- [66] Byrne JLB. 10 multiple pterygium syndrome. In: Woodward PJ, Kennedy A, Sohaey R, Byrne JLB, Oh KY, Puchalski MD, editors. *Diagnostic imaging: obstetrics*. 1st ed. Salt Lake City, UT: Amirsys Inc; 2005. p. 58–9.
- [67] Chen H, Immen L, Lachman R, Yang S, Rimoin DL, Rightmire D, et al. Syndrome of multiple pterygia, camptodactyly, facial anomalies, hypoplastic lungs and heart, cystic hygroma, and skeletal anomalies: delineation of a new entity and review of lethal forms of multiple pterygium syndrome. *Am J Med Genet* 1984;17:809–26.
- [68] Hogge WA, Golabi M, Filly RA, Douglas R, Golbus MS. The lethal multiple pterygium syndromes: is prenatal detection possible? *Am J Med Genet* 1985;20:441–2.
- [69] Zeitune M, Fejgin MD, Abramowicz J, Ben Aderet N, Goodman RM. Prenatal diagnosis of the pterygium syndrome. *Prenat Diagn* 1988;8:145–9.
- [70] Lockwood C, Irons M, Troiani J, Kawada C, Chaudhury A, Cetrulo C. The prenatal sonographic diagnosis of lethal multiple pterygium

- syndrome: a heritable cause of recurrent abortion. *Am J Obstet Gynecol* 1988;159:474–6.
- [71] de Die-Smulders CE, Vonsée HJ, Zandvoort JA, Fryns J- P. The lethal multiple pterygium syndrome: prenatal ultrasonographic and postmortem findings: a case report. *Eur J Obstet Gynecol Reprod Biol* 1990;35:283–9.
- [72] Anthony J, Mascarenhas L, O'Brien J, Battachargee AK, Gould S. Lethal multiple pterygium syndrome. The importance of fetal posture in mid-trimester diagnosis by ultrasound: discussion and case report. *Ultrasound Obstet Gynecol* 1993;3:212–6.
- [73] Meizner I, Hershkovitz R, Carmi R, Katz M. Prenatal ultrasound diagnosis of a rare occurrence of lethal multiple pterygium syndrome in two siblings. *Ultrasound Obstet Gynecol* 1993;3:432–6.
- [74] Sciarrone A, Verdiglione P, Botta G, Franceschini P, Todros T. Prenatal diagnosis of lethal multiple pterygium syndrome in mid-pregnancy. *Ultrasound Obstet Gynecol* 1998;12:218–9.
- [75] Hertzberg BS, Kliewer MA, Paulyson-Nunez K. Lethal multiple pterygium syndrome: antenatal ultrasonographic diagnosis. *J Ultrasound Med* 2000;19:657–60.
- [76] Lembed A, Oktem M, Yilmaz Z, Kaya U, Derbent M. Prenatal diagnosis of multiple pterygium syndrome associated with Klinefelter syndrome. *Prenat Diagn* 2003;23:728–30.
- [77] Chen M, Chan GSW, Lee CP, Tang MHY. Sonographic features of lethal multiple pterygium syndrome at 14 weeks. *Prenat Diagn* 2005;25:475–8.